Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity

Journal of Biological Chemistry

Volumn 287, Issue 52, 2012, Pages 43730-43740

  Madenspacher, Jennifer H ^a   Azzam, Kathleen M ^a   Gongs, Wanghua ^f   Gowdy, Kymberly M ^a   Vitek, Michael P ^c,d   Laskowitz, Daniel T ^c   Remaley, Alan T ^e   Wang, Ji Ming ^b   Fessler, Michael B ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

^d Optimal Screening Vehicles Division   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORIES; ANTI-INFLAMMATORY ACTION; ANTI-INFLAMMATORY MECHANISM; APOLIPOPROTEINS; CALCIUM FLUX; CHEMOTACTIC ACTIVITY; FORMYL PEPTIDE RECEPTOR; INNATE IMMUNE RESPONSE; LIPOPOLYSACCHARIDES; MIMETICS; MUCOSAL SURFACE; MULTIPLE RECEPTORS; STRUCTURE ACTIVITY RELATIONSHIPS; STRUCTURE-FUNCTION RELATIONSHIP;

CALCIUM; CARDIOVASCULAR SYSTEM; IMMUNOLOGY; PEPTIDES;

BIOCHEMISTRY;

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CALCIUM; CHEMOKINE RECEPTOR CXCR2; COG 1410; CXCL1 CHEMOKINE; FORMYLPEPTIDE RECEPTOR; L 37PA PEPTIDE; L 4F PEPTIDE; LIPOPOLYSACCHARIDE; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG;

AIRWAY; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CHEMOTAXIS; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INNATE IMMUNITY; LEUKOCYTE MIGRATION; MONOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIA; NONHUMAN; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; BIOMIMETIC MATERIALS; CALCIUM SIGNALING; CHEMOKINE CXCL1; CHEMOTAXIS; FEMALE; HEK293 CELLS; HUMANS; MICE; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; NEUTROPHILS; PEPTIDES; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS;

EID: 84871564688     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.377192     Document Type: Article

References (50)

1. Murphy, A. J., and Woollard, K. J. (2010) High-density lipoprotein. A potent inhibitor of inflammation. Clin. Exp. Pharmacol. Physiol. 37, 710-718
2. Yvan-Charvet, L., Wang, N., and Tall, A. R. (2010) Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol. 30, 139-143
3. Navab, M., Shechter, I., Anantharamaiah, G. M., Reddy, S. T., Van Lenten, B. J., and Fogelman, A. M. (2010) Structure and function of HDL mimetics. Arterioscler. Thromb. Vasc. Biol. 30, 164-168
4. Dai, L., Datta, G., Zhang, Z., Gupta, H., Patel, R., Honavar, J., Modi, S., Wyss, J. M., Palgunachari, M., Anantharamaiah, G. M., and White, C. R. (2010) The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J. Lipid Res. 51, 2695-2705
5. Getz, G. S., Wool, G. D., and Reardon, C. A. (2010) Biological properties of apolipoprotein A-I mimetic peptides. Curr. Atheroscler. Rep. 12, 96-104
6. Laskowitz, D. T., Fillit, H., Yeung, N., Toku, K., and Vitek, M. P. (2006) Apolipoprotein E-derived peptides reduce CNS inflammation. Implications for therapy of neurological disease. Acta Neurol. Scand Suppl. 185, 15-20 (Pubitemid 44015220)
7. Yao, X., Dai, C., Fredriksson, K., Dagur, P. K., McCoy, J. P., Qu, X., Yu, Z. X., Keeran, K. J., Zywicke, G. J., Amar, M. J., Remaley, A. T., and Levine, S. J. (2011) 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J. Immunol. 186, 576-583
8. Wang, W., Xu, H., Shi, Y., Nandedkar, S., Zhang, H., Gao, H., Feroah, T., Weihrauch, D., Schulte, M. L., Jones, D. W., Jarzembowski, J., Sorci-Thomas, M., and Pritchard, K. A., Jr. (2010) Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J. Lipid Res. 51, 2560-2570
9. Yao, X., Fredriksson, K., Yu, Z. X., Xu, X., Raghavachari, N., Keeran, K. J., Zywicke, G. J., Kwak, M., Amar, M. J., Remaley, A. T., and Levine, S. J. (2010) Apolipoprotein E negatively regulates house dust mite-induced asthma via a low-density lipoprotein receptor-mediated pathway. Am. J. Respir Crit. Care Med. 182, 1228-1238
10. Bocharov, A. V., Baranova, I. N., Vishnyakova, T. G., Remaley, A. T., Csako, G., Thomas, F., Patterson, A. P., and Eggerman, T. L. (2004) Targeting of scavenger receptor class B type I by synthetic amphipathic alpha-helical- containing peptides blocks lipopolysaccharide (LPS) uptake and LPS-induced pro-inflammatory cytokine responses in THP-1 monocyte cells. J. Biol. Chem. 279, 36072-36082 (Pubitemid 39100615)
11. Remaley, A. T., Thomas, F., Stonik, J. A., Demosky, S. J., Bark, S. E., Neufeld, E. B., Bocharov, A. V., Vishnyakova, T. G., Patterson, A. P., Eggerman, T. L., Santamarina-Fojo, S., and Brewer, H. B. (2003) Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J. Lipid Res. 44, 828-836 (Pubitemid 37279685)
12. Brewer, H. B., Jr., Ronan, R., Meng, M., and Bishop, C. (1986) Isolation and characterization of apolipoproteins A-I, A-II, and A-IV. Methods Enzymol. 128, 223-246 (Pubitemid 16100894)
13. Gao, J., Wang, H., Sheng, H., Lynch, J. R., Warner, D. S., Durham, L., Vitek, M. P., and Laskowitz, D. T. (2006) A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocrit. Care 4, 25-31 (Pubitemid 43269458)
14. Laskowitz, D. T., McKenna, S. E., Song, P., Wang, H., Durham, L., Yeung, N., Christensen, D., and Vitek, M. P. (2007) COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J. Neurotrauma 24, 1093-1107 (Pubitemid 47106284)
15. Smoak, K., Madenspacher, J., Jeyaseelan, S., Williams, B., Dixon, D., Poch, K. R., Nick, J. A., Worthen, G. S., and Fessler, M. B. (2008) Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J. Immunol. 180, 3305-3312
16. Deng, X., Ueda, H., Su, S. B., Gong, W., Dunlop, N. M., Gao, J. L., Murphy, P. M., and Wang, J. M. (1999) A synthetic peptide derived from human immunodeficiency virus type 1 gp120 down-regulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Blood 94, 1165-1173 (Pubitemid 29380396)
17. Su, S. B., Gong, W., Gao, J. L., Shen, W., Murphy, P. M., Oppenheim, J. J., and Wang, J. M. (1999) A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 189, 395-402 (Pubitemid 29063260)
18. Yan, Y. J., Li, Y., Lou, B., and Wu, M. P. (2006) Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci. 79, 210-215 (Pubitemid 43737069)
19. Kim, T. H., Lee, Y. H., Kim, K. H., Lee, S. H., Cha, J. Y., Shin, E. K., Jung, S., Jang, A. S., Park, S. W., Uh, S. T., Kim, Y. H., Park, J. S., Sin, H. G., Youm, W., Koh, E. S., Cho, S. Y., Paik, Y. K., Rhim, T. Y., and Park, C. S. (2010) Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis. Anti-inflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am. J. Respir. Crit. Care Med. 182, 633-642
20. Lin, C. T., Xu, Y. F., Wu, J. Y., and Chan, L. (1986) Immunoreactive apolipoprotein E is a widely distributed cellular protein. Immunohistochemical localization of apolipoprotein E in baboon tissues. J. Clin. Invest. 78, 947-958
21. Diederich, W., Orsó, E., Drobnik, W., and Schmitz, G. (2001) Apolipoprotein AI and HDL3 inhibit spreading of primary human monocytes through a mechanism that involves cholesterol depletion and regulation of CDC42. Atherosclerosis 159, 313-324 (Pubitemid 33127245)
22. Bursill, C. A., Castro, M. L., Beattie, D. T., Nakhla, S., van der Vorst, E., Heather, A. K., Barter, P. J., and Rye, K. A. (2010) High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 30, 1773-1778
23. Blackburn, W. D., Jr., Dohlman, J. G., Venkatachalapathi, Y. V., Pillion, D. J., Koopman, W. J., Segrest, J. P., and Anantharamaiah, G. M. (1991) Apolipoprotein A-I decreases neutrophil degranulation and superoxide production. J. Lipid Res. 32, 1911-1918
24. Migeotte, I., Communi, D., and Parmentier, M. (2006) Formyl peptide receptors. A promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 17, 501-519 (Pubitemid 44793122)
25. Le, Y., Oppenheim, J. J., and Wang, J. M. (2001) Pleiotropic roles of formyl peptide receptors. Cytokine Growth Factor Rev. 12, 91-105 (Pubitemid 32294589)
26. Zhang, Z., Cherryholmes, G., Chang, F., Rose, D. M., Schraufstatter, I., and Shively, J. E. (2009) Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. Eur. J. Immunol. 39, 3181-3194
27. Hu, J. Y., Le, Y., Gong, W., Dunlop, N. M., Gao, J. L., Murphy, P. M., and Wang, J. M. (2001) Synthetic peptide MMK-1 is a highly specific chemotactic agonist for leukocyte FPRL1. J. Leukoc. Biol. 70, 155-161 (Pubitemid 32613676)
28. Datta, G., Chaddha, M., Hama, S., Navab, M., Fogelman, A. M., Garber, D. W., Mishra, V. K., Epand, R. M., Epand, R. F., Lund-Katz, S., Phillips, M. C., Segrest, J. P., and Anantharamaiah, G. M. (2001) Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 42, 1096-1104 (Pubitemid 32645791)
29. Ye, R. D., Boulay, F., Wang, J. M., Dahlgren, C., Gerard, C., Parmentier, M., Serhan, C. N., and Murphy, P. M. (2009) International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61, 119-161
30. Chiang, N., Serhan, C. N., Dahlén, S. E., Drazen, J. M., Hay, D. W., Rovati, G. E., Shimizu, T., Yokomizo, T., and Brink, C. (2006) The lipoxin receptor ALX. Potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58, 463-487 (Pubitemid 44394909)
31. Ying, G., Iribarren, P., Zhou, Y., Gong, W., Zhang, N., Yu, Z. X., Le, Y., Cui, Y., and Wang, J. M. (2004) Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J. Immunol. 172, 7078-7085 (Pubitemid 38669150)
32. Le, Y., Gong, W., Li, B., Dunlop, N. M., Shen, W., Su, S. B., Ye, R. D., and Wang, J. M. (1999) Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J. Immunol. 163, 6777-6784
33. Bloedon, L. T., Dunbar, R., Duffy, D., Pinell-Salles, P., Norris, R., DeGroot, B. J., Movva, R., Navab, M., Fogelman, A. M., and Rader, D. J. (2008) Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49, 1344-1352
34. Tabet, F., Remaley, A. T., Segaliny, A. I., Millet, J., Yan, L., Nakhla, S., Barter, P. J., Rye, K. A., and Lambert, G. (2010) The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler. Thromb. Vasc. Biol. 30, 246-252
35. Murphy, P. M., Ozçelik, T., Kenney, R. T., Tiffany, H. L., McDermott, D., and Francke, U. (1992) A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family. J. Biol. Chem. 267, 7637-7643
36. Ye, R. D., Cavanagh, S. L., Quehenberger, O., Prossnitz, E. R., and Cochrane, C. G. (1992) Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. Biochem. Biophys. Res. Commun. 184, 582-589
37. Lee, H. Y., Kim, S. D., Shim, J. W., Lee, S. Y., Lee, H., Cho, K. H., Yun, J., and Bae, Y. S. (2008) Serum amyloid A induces CCL2 production via formyl peptide receptor-like 1-mediated signaling in human monocytes. J. Immunol. 181, 4332-4339
38. Filep, J. G., and El Kebir, D. (2009) Neutrophil apoptosis. A target for enhancing the resolution of inflammation. J. Cell Biochem. 108, 1039-1046
39. Bae, Y. S., Yi, H. J., Lee, H. Y., Jo, E. J., Kim, J. I., Lee, T. G., Ye, R. D., Kwak, J. Y., and Ryu, S. H. (2003) Differential activation of formyl peptide receptor-like 1 by peptide ligands. J. Immunol. 171, 6807-6813 (Pubitemid 37532115)
40. Bürli, R. W., Xu, H., Zou, X., Muller, K., Golden, J., Frohn, M., Adlam, M., Plant, M. H., Wong, M., McElvain, M., Regal, K., Viswanadhan, V. N., Tagari, P., and Hungate, R. (2006) Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med. Chem. Lett. 16, 3713-3718 (Pubitemid 44137222)
41. Sogawa, Y., Ohyama, T., Maeda, H., and Hirahara, K. (2011) Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist. Indication of cross-desensitization in vivo. Immunology 132, 441-450
42. Sogawa, Y., Ohyama, T., Maeda, H., and Hirahara, K. (2011) Formyl peptide receptor 1 and 2 dual agonist inhibits human neutrophil chemotaxis by the induction of chemoattractant receptor cross-desensitization. J. Pharmacol. Sci. 115, 63-68
43. Klein, C., Paul, J. I., Sauvé, K., Schmidt, M. M., Arcangeli, L., Ransom, J., Trueheart, J., Manfredi, J. P., Broach, J. R., and Murphy, A. J. (1998) Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. Nat. Biotechnol. 16, 1334-1337 (Pubitemid 28547443)
44. Le, Y., Jiang, S., Hu, J., Gong, W., Su, S., Dunlop, N. M., Shen, W., Li, B., and Ming Wang, J. (2000) N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes. Clin. Immunol. 96, 236-242
45. Shen, W., Proost, P., Li, B., Gong, W., Le, Y., Sargeant, R., Murphy, P. M., Van Damme, J., and Wang, J. M. (2000) Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR5 and attenuates cell responses to selected chemokines. Biochem. Biophys. Res. Commun. 272, 276-283 (Pubitemid 30444934)
46. Ahuja, S. K., and Murphy, P. M. (1996) The CXC chemokines growth-regulated oncogene (GRO) α, GROβ, GROγ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 271, 20545-20550
47. Foxman, E. F., Campbell, J. J., and Butcher, E. C. (1997) Multistep navigation and the combinatorial control of leukocyte chemotaxis. J. Cell Biol. 139, 1349-1360 (Pubitemid 27523220)
48. Chen, K., Le, Y., Liu, Y., Gong, W., Ying, G., Huang, J., Yoshimura, T., Tessarollo, L., and Wang, J. M. (2010) A critical role for the G protein-coupled receptor mFPR2 in airway inflammation and immune responses. J. Immunol. 184, 3331-3335
49. Marshall, G. R., Hodgkin, E. E., Langs, D. A., Smith, G. D., Zabrocki, J., and Leplawy, M. T. (1990) Factors governing helical preference of peptides containing multiple α,α-dialkyl amino acids. Proc. Natl. Acad. Sci. U.S.A. 87, 487-491
50. Christensen, D. J., Ohkubo, N., Oddo, J., Van Kanegan, M. J., Neil, J., Li, F., Colton, C. A., and Vitek, M. P. (2011) Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J. Immunol. 186, 2535-2542